BioInformant

Your Global Leader in Stem Cell Market Research

Home » iPS cells

Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating iPS Cells

By

Lineage Cell and AgeX get issued U.S. Patent that Precedes the first scientific publication of Shinya Yamanaka.

CARLSBAD, Calif., Dec 10, 2019 — Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells” covering what is commonly designated “induced Pluripotent Stem (iPS) cells.” The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body.

The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012. [Read more…]

Synthego Launches High-Throughput Induced Pluripotent Stem Cell Genome Engineering

By

National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer’s, Stem cell pioneer Bill Skarnes joins advisory board

REDWOOD CITY, Calif., Oct. 22, 2019 — Synthego, the leading genome engineering company, announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale. [Read more…]

Century Therapeutics Launches With $250 Million for Allogeneic iPSC Platform

By

  • Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies

  • Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments

July 01, 2019, LEVERKUSEN, Germany & PHILADELPHIA & TOKYO–Century Therapeutics, which was created by Versant Ventures as part of the firm’s core strategy to launch innovative biotech companies, emerged from stealth mode today with USD 250 million in financing commitments from Bayer, Versant and Fujifilm Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies. [Read more…]

Development of iPSC-derived Disease Models

By

Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]

Celgene to Pay Evotec $9 Million as Companies Expand iPSC Collaboration

By

Hamburg, Germany, June 5, 2019 — Evotec SE announced that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $9.0 m to Evotec.

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one programme into lead optimisation as well as including additional cell lines and now a new cell type. [Read more…]

BioInformant's World-Class Clients